Rytwiany (PL)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~46 mi. (Kielce, Poland, +176 more cities)
facility
Swietokrzyskie Centrum Onkologii SPZOZ ( Site 2485)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~50 mi. (Tarnów, Poland, +163 more cities)
facility
Szpital Wojewodzki ( Site 1062)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~81 mi. (Radom, Poland, +144 more cities)
facility
Radomskie Centrum Onkologii ( Site 2418)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
city
~87 mi. (Kraków, Poland, +93 more cities)
facility
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 240
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +1 more drug
drug type
targeted therapy
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~87 mi. (Kraków, Poland, +150 more cities)
facility
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0905)
condition
Head and Neck Squamous Cell Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~87 mi. (Kraków, Poland, +137 more cities)
facility
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 0959)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~87 mi. (Kraków, Poland, +127 more cities)
facility
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2502)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~87 mi. (Kraków, Poland, +92 more cities)
facility
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0153)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~87 mi. (Kraków, Poland, +145 more cities)
facility
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2400)
condition
Non-Small Cell Lung Carcinoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types